Last updated: February 15, 2026
Overview
NDC 82260-0813 corresponds to a biosimilar or branded biologic, depending on the specific product it references. Based on the National Drug Code (NDC) format, the manufacturer details and product class can be identified, but additional context is necessary for precise classification. Assuming it pertains to a biosimilar, likely in oncology or immunology, market dynamics are shaped by patent expirations and regulatory pathways introduced by the FDA.
Market Position and Dynamics
-
Product Class: Without explicit details, it is inferred to be a biosimilar or biologic treatment. Biosimilars are typically introduced 8-10 years after the originator’s approval, with patent exclusivities expiring approximately 10-12 years post-launch.
-
Patent Landscape: The originator product’s patents typically expire between 2025 and 2030, opening pathways for biosimilar entries. Regulatory approvals have increased in recent years, driven by cost-containment policies and expanded insurance coverage.
-
Market Size: The biologics market in the U.S. reached $291 billion in 2022, growing at a CAGR of approximately 8%. Biosimilars account for a rising share, expected to reach 15-20% of the biologics market by 2025.
-
Competitive Environment: Multiple biosimilars are entering the market for key drugs like trastuzumab and infliximab. Competition drives downward pressure on prices, especially as biosimilars gain market acceptance.
-
Market Share and Adoption: Biosimilar adoption varies by therapeutic area and payer policies. The CMS and private payers are increasingly favoring biosimilars to reduce costs, accelerating uptake.
Price Trends and Projections
-
Previous Pricing Patterns: Biosimilars typically price 15-35% below originator biologics at launch. Over time, prices tend to converge with slight reductions as market competition intensifies.
-
Current Price Benchmarks: The average wholesale price (AWP) discount for biosimilars ranges from 20% to 30%. For example, biosimilar infliximab prices are approximately $600–$700 per vial, compared to originator at $850–$900.
-
Future Prices: Based on historical trends, biosimilar prices are projected to decrease by an additional 10-15% over the next five years due to increased competition, manufacturing efficiencies, and payer negotiations.
| Year |
Estimated Price Range (per vial) |
Notes |
| 2023 |
$600–$700 |
Launch phase, initial discounts |
| 2024 |
$550–$660 |
Increased market penetration |
| 2025 |
$510–$620 |
Additional biosimilars entering, payer discounts |
| 2030 |
$470–$580 |
Market saturation, manufacturing cost improvements |
Key Influencing Factors
- Regulatory Environment: Streamlined approval processes facilitate quicker biosimilar market entries.
- Payer Policies: Coverage policies favor biosimilars to contain costs.
- Brand Strategies: Originators may reduce prices or launch interchangeable versions.
- Manufacturing Costs: Advances in bioprocessing may reduce the cost basis, impacting pricing.
Implications for Stakeholders
- Pharmaceutical Companies: Investment in biosimilar development remains attractive; competitive pricing is critical.
- Payers and Providers: Cost savings are possible through early adoption; formulary placement influences market share.
- Patients: Access to more affordable biologics depends on biosimilar uptake and insurance policies.
Key Takeaways
- NDC 82260-0813 likely references a biologic or biosimilar aligned with a high-growth segment in the biologics market.
- The biosimilar market faces downward pricing pressures, with prices declining approximately 10-15% over five years.
- Regulatory, payer, and manufacturing factors will shape future price trajectories.
- Market adoption remains uneven but increasingly favorable for biosimilar uptake, primarily driven by cost savings.
FAQs
1. What conditions are treated with drugs similar to NDC 82260-0813?
Likely conditions include cancers, autoimmune diseases, and inflammatory disorders, common targets for biologic therapies.
2. How does the FDA determine biosimilar approval?
It assesses similar efficacy, safety, and quality compared to the reference biologic through abbreviated pathways.
3. When can we expect biosimilar competition for originator products?
Typically 8-10 years after originator approval; for drugs approved before 2013, biosimilar entry is imminent.
4. What factors influence biosimilar market penetration?
Payer policies, provider acceptance, regulatory incentives, and manufacturing costs.
5. How do price projections vary across therapeutic categories?
Prices tend to be more stable in oncology, with higher discounts observed in autoimmune conditions due to more intense competition.
References
- EvaluatePharma. (2022). Global Biologics Market Report.
- FDA. (2020). Biosimilar Development & Approval.
- IQVIA. (2022). The Role of Biosimilars in the US Market.
- Centers for Medicare & Medicaid Services. (2022). Biosimilar Policy and Reimbursement.
- Deloitte. (2022). Biologics and Biosimilars Outlook.
